Quantcast

3-(4′-bromobenzylindenyl)-2-indolinone and analogues thereof for the treatment of disease

Imported: 23 Feb '17 | Published: 22 Oct '02

Peng Cho Tang, Li Sun, Gerald McMahon

USPTO - Utility Patents

Abstract

The present invention relates to organic molecules capable of modulating tyrosine kinase signal transduction in order to regulate, modulate and/or inhibit abnormal cell proliferation.

Claims

1. A method of treating ocular disease comprising administering to a patient in need thereof a pharmaceutically acceptable amount of a compound having the formula:

and pharmaceutically acceptable salt thereof, wherein

2. A method of treating ocular disease comprising administering to a patient in need thereof a pharmaceutically acceptable amount of a compound having the formula:

and pharmaceutically acceptable salts thereof, wherein

3. A method of treating ocular disease comprising administering to a patient in need thereof a pharmaceutically acceptable amount of a compound having the formula:

and pharmaceutically acceptable salts thereof, wherein

4. A method of treating ocular disease comprising administering to a patient in need thereof a pharmaceutically acceptable amount of a compound having the formula:

and pharmaceutically acceptable salts thereof, wherein

5. A method of treating ocular disease comprising administering to a patient in need thereof a pharmaceutically acceptable amount of a compound having the formula:

and pharmaceutically acceptable salts thereof, wherein

6. A method of treating ocular disease comprising administering to a patient in need thereof a pharmaceutically acceptable amount of a compound having the formula:

or a pharmaceutically acceptable salt thereof, wherein:

7. A method of treating ocular disease comprising administering to a patient in need thereof a pharmaceutically acceptable amount of a compound having the formula:

or a pharmaceutically acceptable salt thereof, wherein:

8. A method of treating ocular disease comprising administering to a patient in need thereof a pharmaceutically acceptable amount of a compound having the formula:

or a pharmaceutically acceptable salt thereof, wherein:

9. A method of treating ocular disease comprising administering to a patient in need thereof a pharmaceutically acceptable amount of a compound having the formula:

or a pharmaceutically acceptable salt thereof, wherein:

10. The method of claim 3, wherein A is a five-membered heterocyclic moiety.

11. The method of claim 1, wherein the ocular disease is diabetic retinopathy.

12. The method of claim 2, wherein the ocular disease is diabetic retinopathy.

13. The method of claim 3, wherein the ocular disease is diabetic retinopathy.

14. The method of claim 4, wherein the ocular disease is diabetic retinopathy.

15. The method of claim 5, wherein the ocular disease is diabetic retinopathy.

16. The method of claim 6, wherein the ocular disease is diabetic retinopathy.

17. The method of claim 7, wherein the ocular disease is diabetic retinopathy.

18. The method of claim 8, wherein the ocular disease is diabetic retinopathy.

19. The method of claim 1, wherein R

3′, is selected from the group consisting of methyl, ethyl, n-propyl, iso-propyl, n-butyl, iso-butyl, tert-butyl, halogen, aryl, and OR, where R is H, alkyl, or aryl and

20. The method of claim 2, wherein R

3′, is selected from the group consisting of methyl, ethyl, n-propyl, iso-propyl, n-butyl, iso-butyl, tert-butyl, halogen, aryl, and OR, where R is H, alkyl, or aryl and

21. The method of claim 4, wherein R

3′, is selected from the group consisting of methyl, ethyl, n-propyl, iso-propyl, n-butyl, iso-butyl, tert-butyl, halogen, aryl, and OR, where R is H, alkyl, or aryl and

22. The method of claim 5, wherein R

3′ is selected from the group consisting of methyl, ethyl, n-propyl, iso-propyl, n-butyl, iso-butyl, tert-butyl, halogen, aryl, and OR, where R is H, alkyl, or aryl and

23. The method of claim 6, wherein R

3′, is selected from the group consisting of methyl, ethyl, n-propyl, iso-propyl, n-butyl, iso-butyl, tert-butyl, halogen, aryl, and OR, where R is H, alkyl, or aryl and

24. The method of claim 7, wherein R

3′, is selected from the group consisting of methyl, ethyl, n-propyl, iso-propyl, n-butyl, iso-butyl, tert-butyl, halogen, aryl, and OR, where R is H, alkyl, or aryl and

25. The method of claim 8, wherein R

3′, is selected from the group consisting of methyl, ethyl, n-propyl, iso-propyl, n-butyl, iso-butyl, tert-butyl, halogen, aryl, and OR, where R is H, alkyl, or aryl and